Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab in Refractory ANCA-Associated Vasculitis
NCT01405807Phase 4Unknown
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Feb 2011
- Primary completion
- Mar 2014
- Countries
- 1
01
Overview
A Phase 4 trial of alemtuzumab in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), sponsored by Cambridge University Hospitals NHS Foundation Trust. Status: unknown.
02
Drugs
alemtuzumab
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)microscopic polyangiitis (MPA)granulomatosis with polyangiitis (GPA)
Beyond the preview
Go deeper on NCT01405807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01405807.